

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: Lexaria Bioscience Corp. (the "Issuer").

Trading Symbol: LXX

Number of Outstanding Listed Securities: 78,437,134

Date: June 4, 2019.

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

Lexaria Bioscience Corp. ("Lexaria") has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds. Lexaria has multiple patents pending in over 40 countries around the world and was granted its first patent in the USA in October, 2016. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including but not limited to cannabinoids, vitamins, NSAIDs, and nicotine.

Lexaria and its subsidiaries are not involved directly or indirectly in the cultivation, processing, distribution, or utilization of cannabis or cannabis derived components. All of Lexaria's consumer products utilize legally sourced hemp and hemp components in their production. Lexaria does have an ancillary involvement risk via out-licensing of its patented technology to licensees that choose to utilize its technology to manufacture products that contain locally or state approved but federally regulated and controlled contents. There can be no guarantee that changes in the regulatory framework and environment will not occur and such changes could have a materially adverse effect on the Company. It is possible some jurisdictions may even interpret Lexaria's ancillary involvement as in contravention with regulations.

On May 1, 2019 the board of directors approved a new equity incentive plan (the "Plan") which provides for incentive-based equity for eligible participants resulting in up to an aggregate of 7,838,713 common shares in the authorized share capital of Lexaria being issued thereto. Equity awards issued under the Plan may not have a term that is longer than ten (10) years which term if further reduced to a maximum of five (5) years for individuals who hold 10% or more of Lexaria's issued share capital, and must be issued with an exercise / issue price of the greater of the fair market value on either the day prior to or the day of the stock award issuance, and for persons holding 10% or more of Lexaria's issued share capital the exercise / issue price must not be less than 110% of the fair market value on the date of the award grant

On May 6, 2019, Lexaria issued 790,000 incentive stock options (the "Options") to certain directors, employees and consultants of Lexaria, with an exercise price of US\$0.99 per share and a five (5) year term. The Options will vest as to 510,000 immediately, 60,000 on November 26, 2019, 50,000 on April 15, 2020, 60,000 on November 26, 2020, 50,000 on April 15, 2021 and 60,000 on November 26, 2021. The Options are also subject to a four month hold period pursuant to Canadian Securities Exchange policy.

For full details please see the Press Release dated May 7, 2019 and the Form 11 – Notice of Proposed Stock Option Grant or Amendment filed on these.com website.

On May 15, 2019 Lexaria also entered into, via its subsidiaries, an amended and a new license agreement with its current licensee, Nuka Enterprises LLC ("Nuka"). The amended agreement between Nuka and Lexaria CanPharm ULC expands Nuka's semi-exclusive rights to use our DehydraTech™

technology to additional US States and product lines that contain 0.3% or more of THC.

The new agreement between Nuka and Lexaria Hemp Corp. provides Nuka with the right to use our DehydraTech™ technology on a non-exclusive basis throughout the United States for the production of beverages that contain 0.29% or less of THC.

For full details please see the Press Release dated May 21, 2019.

On May 22, 2019 Lexaria issued 48,000 Options to one of its consultants. The Options are exercisable for a period of five (5) years and have an exercise price of US\$0.96 per share. The Options are subject to the following vesting schedule: 16,000 Options are exercisable immediately; 16,000 Options are exercisable as at Feb. 24, 2020; and 16,000 Options are exercisable as at Feb. 24, 2021. The Options will be subject to a four month hold period pursuant to Canadian Securities Exchange policy.

On May 22, 2019 Lexaria issued 100,000 share purchase warrants (“Warrants”) to Oak Hill Financial Services Inc. (“Oak Hill”). The Warrants are exercisable to purchase common shares at a price of US\$0.96 per share for a period of two (2) years. The Warrants will be subject to a four month hold period pursuant to Canadian Securities Exchange policy.

For full details regarding the May 22, 2019 Option and Warrant issuances see the Press Release dated May 23, 2019, the Form 9 – Notice of Issuance or Proposed Issuance of Securities and the Form 11 – Notice of Proposed Stock Option Grant or Amendment filed on thecse.com website.

2. Provide a general overview and discussion of the activities of management.

Please refer to #1 above.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

See Item #1 above for details regarding new licensing arrangements with Nuka.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable.

8. Describe the acquisition of new customers or loss of customers.

Not Applicable.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

On May 15, 2019 Lexaria announced that its animal study produced results evidencing that its DehydraTech™ technology produces faster delivery of

cannabinoids (“CBD”) in the bloodstream with higher rates of absorption via edible products than current conventional industry formulations, namely ones using coconut oil and MCT oil. At the completion of the 60 minute study it was found that edibles prepared with the DehydraTech™ technology resulted in an average maximum CBD blood concentration that was 334% more than the average maximum CBD blood concentration found in subjects that consumed edibles that used the MCT oil formulation and that the total quantity of CBD delivered using the DehydraTech™ technology was 389% more than those using the MCT oil formulation. On May 28, 2019 Lexaria announced further results of its animal study which were received through the combination of its DehydraTech™ technology and nanoemulsion. This combination of technologies indicated that levels of CBD observed in the average brain tissue of the animals were 1,137% higher than the levels of CBD observed in the average brain tissue of animals that received an MCT oil formulation.

For full details please see the Press Releases dated May 15 and May 28, 2019.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.
Not Applicable.
11. Report on any labour disputes and resolutions of those disputes if applicable.
Not Applicable.
12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.
Not Applicable.
13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.
Not Applicable.
14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds⁽¹⁾
Common Shares	50,000	50,000 Options Exercised at US\$0.295	US\$14,750.00
Options	790,000	See item #1	N/A
Options	48,000	See item #1	N/A
Warrants	100,000	See item #1	N/A

(1) The Issuer intends to use the aggregate proceeds of US\$14,750.00 for its general working capital.

15. Provide details of any loans to or by Related Persons.

Not Applicable.

16. Provide details of any changes in directors, officers or committee members.

By resolutions effective as of April 29, 2019, the following directors were confirmed as audit committee members: Christopher Bunka, Ted McKechnie and Nicholas Baxter.

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The issuer has sufficient funds for the current fiscal year, but may need to raise additional funds to continue operations thereafter.

The US Federal Government passed the 2018 Farm Bill that may have significant positive impacts on industry segments that we operate and have products in and potentially change some of the regulatory compliance risks that may affect our business. The Bill includes lifting restrictions on advertising, marketing, banking and other financial services as well as allowing interstate commerce for hemp and hemp derived cannabidiol (CBD), removal of barriers for intellectual property protections under federal law such as patents and trademarks, as well as several other measures that may positively impact these industry segments overall. The impact the Bill may have on other regulatory bodies and their regulations will require ongoing monitoring to determine the outcome and timing of any revisions.

On February 27, 2019, The United States Department of Agriculture ("USDA") issued a Hemp Production Program Notice to Trade advising that it was the USDA's intent to issue regulations in the Fall of 2019 to accommodate the 2020 planting season.

On April 25, 2019 the Alcohol and Tobacco Trade Bureau distributed an industry circular advising that it would defer to the guidance issued from the U.S. Food and Drug Administration ("FDA") as it works to re-evaluate

whether CBD can be safely permitted in food, beverages, dietary supplements and cosmetics.

On May 31, 2019 the FDA held a public forum to discuss unanswered questions concerning products containing cannabis and cannabis-derived compounds. The forum is to act as a foundation for the appointed working group tasked with assessing the available options for the safe use of CBD ingestible product. The working group is expected to share its initial information and findings as early as the summer of 2019.

The Issuer is not aware of any other trends that manifested themselves in the past month that have an impact on its business or markets, other than general market volatility.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 4, 2019.

Chris Bunka
Name of Director or Senior
Officer

"Chris Bunka"
Signature

Chief Executive Officer
Official Capacity

Issuer Details	For Month End	Date of Report
Name of Issuer LEXARIA BIOSCIENCE CORP.	May 31, 2019	YY/MM/D 19/06/04
Issuer Address #100, 740 McCurdy Road		
City/Province/Postal Code Kelowna, BC V1X 2P7	Issuer Fax No. (250) 765-2599	Issuer Telephone No. (250) 765-6424
Contact Name Alex Blanchard	Contact Position Manager Corporate Communications	Contact Telephone No. (250) 765-6424
Contact Email Address ir@lexariabioscience.com	Web Site Address www.lexariabioscience.com	